PURLs: Need an add-on to metformin? Consider this.

David Wyncott, Corey Lyon, Anne Mounsey

Abstract readCase ReportsComment

In one paragraph

Article in The Journal of family practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Predictors of HbAScientific reports · 2023
Article

4 · The record

Corrections and comments

Comment on
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.2015

5 · Who and what money

Authors and funding

3 authors.

David WyncottSaint Joseph Health System Family Medicine Residency, Mishawaka, IN, USA.

Corey LyonUniversity of Colorado Family Medicine Residency, Denver, CO, USA.

Anne MounseyDepartment of Family Medicine, University of North Carolina, Chapel Hill, NC, USA.

Funding

TRANSLATIONAL RESEARCH UNIVERSITY OF CHICAGO: CLINICAL TRIALSUL1RR024999 · NCRR · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2007 to 2011

$25.3M

NCRR NIH HHS UL1 RR024999

6 · The paper itself

Abstract

Sulfonylureas have been the preferred add-on therapy to metformin for T2DM, but a study finds that DPP-4s have lower risks of death, CV events, and hypoglycemia.

Indexed as

Drug Therapy, CombinationDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleHumansHypoglycemic AgentsMetforminMiddle AgedRisk FactorsSulfonylurea CompoundsTreatment OutcomeDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetforminSulfonylurea Compounds

Identifiers

PMID28188318

PMCPMC5329113

What OpenQuestion holds

Texttitle and abstract

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.